SAN DIEGO, Calif., Oct. 22, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new open-label
extension data from the Phase 2 OASIS trial for its investigative
drug candidate etrasimod, a next-generation, once-daily, oral,
selective sphingosine 1-phosphate (S1P) receptor modulator, in
patients with moderately to severely active ulcerative colitis (UC)
at the 25th Annual United European Gastroenterology
(UEG) Week.
"We are delighted to see that most patients who achieved
clinical response, clinical remission, or endoscopic improvement at
week 12 experienced sustained or improved effects up to week 46
with etrasimod 2 mg in the open-label extension of our Phase 2
OASIS trial. Etrasimod also demonstrated a favorable safety
profile, consistent with safety findings reported in the
double-blind portion of OASIS," stated Dr. Preston Klassen, Executive Vice President, Head
of Research & Development at Arena. "These data support
the growing body of evidence that etrasimod has potential as a safe
and effective treatment for the sustained management of UC.
We look forward to providing updates as we advance our global Phase
3 ELEVATE UC program."
Etrasimod Presentation Details:
Title: Long-term Efficacy and Safety of Etrasimod for
Ulcerative Colitis: Results from the Open- label Extension of
the OASIS Study
Presenting Author: Dr. Séverine Vermeire
About Etrasimod
Etrasimod (APD334) is a once-daily, oral, selective sphingosine
1-phosphate (S1P) receptor modulator, discovered by Arena, designed
to provide systemic and local cell modulation by targeting S1P
receptor subtypes 1, 4 and 5. Etrasimod has therapeutic potential
in immune and inflammatory-mediated diseases such as ulcerative
colitis, Crohn's disease, and atopic dermatitis. S1P receptors have
been demonstrated to be involved in the modulation of several
biological responses, including lymphocyte trafficking from lymph
nodes to the peripheral blood. By isolating subpopulations of
lymphocytes in lymph nodes, fewer immune cells are available in the
circulating blood to effect tissue damage.
Etrasimod is an investigational compound that is not approved
for any use in any country.
About Arena Pharmaceuticals
Arena Pharmaceuticals is driven to deliver novel, transformational
medicines with optimized pharmacology to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility.
Etrasimod (APD334), with potential utility in a broad range of
immune-mediated and inflammatory conditions, is being evaluated in
later-stage clinical programs in ulcerative colitis (UC) and
Crohn's disease (CD), as well as in programs for other indications
such as atopic dermatitis. Arena is also evaluating olorinab
(APD371) in a Phase 2 program for gastrointestinal pain. Arena
continues to assess other earlier research and development stage
drug candidates, including APD418 for decompensated heart
failure.
Arena has additional license agreements and partnerships,
including with United Therapeutics (ralinepag in a Phase 3 program
for pulmonary arterial hypertension), Everest Medicines Limited
(etrasimod in Greater China and
select Asian countries), Boehringer Ingelheim International GmbH
(undisclosed target – preclinical), Outpost Medicine, LLC
(undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai
Inc. (BELVIQ® – marketed product).
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. These
forward-looking statements may be identified by introductory words
such as "potential," "look forward to," "designed to," "driven to,"
"potentially," "evaluating," or words of similar meaning, or by the
fact that they do not relate strictly to historical or current
facts. Such forward-looking statements include, without limitation,
statements about etrasimod, including its potential to be a safe
and effective treatment, future updates from Arena, and progress in
the Phase 3 ELEVATE UC program; Arena's drive; and the potential of
Arena's assets, programs, licenses, and partnerships. For such
statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking
statements include, without limitation, the following: the
announced data may not accurately reflect the final results of the
open-label extension study or the Phase 3 ELEVATE UC study; results
of clinical trials and other studies are subject to different
interpretations and may not be predictive of future results;
nonclinical and clinical data are voluminous and detailed, and
regulatory agencies may interpret or weigh the importance of data
differently and reach different conclusions than Arena or others,
request additional information, have additional recommendations or
change their guidance or requirements before or after approval; the
timing and outcome of research, development and regulatory review
is uncertain; we expect to need additional funds to advance all of
our programs, and you and others may not agree with the manner we
allocate our resources; our drug candidates may not advance in
development or be approved for marketing; clinical trials and other
studies may not proceed at the time or in the manner expected or at
all; enrolling patients in our ongoing and intended clinical trials
is competitive and challenging; risks related to unexpected or
unfavorable new data; risks related to developing and
commercializing drugs; risks related to relying on partners and
other third parties; Arena's and third parties' intellectual
property rights; and satisfactory resolution of litigation or other
disagreements with others. Additional factors that could cause
actual results to differ materially from those stated or implied by
Arena's forward-looking statements are disclosed in Arena's filings
with the Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presented-new-data-analyses-demonstrating-the-long-term-safety-and-efficacy-of-once-daily-etrasimod-in-patients-with-moderately-to-severely-active-ulcerative-colitis-at-ueg-week-300943368.html
SOURCE Arena Pharmaceuticals, Inc.